We recently published a list of 10 Best Healthcare Stocks For Long-Term Investment. In this article, we are going to take a ...

Mergers and acquisitions grabbed the spotlight in the biotech sector once again this week after Bristol Myers Squibb BMY agreed to acquire 2seventy bio, Inc TSVT. Meanwhile, other pipeline and ...

J.P. Morgan analyst Brian Cheng maintained a Buy rating on Protagonist Therapeutics (PTGX – Research Report) yesterday and set a price target ...

Protagonist Therapeutics (NASDAQ:PTGX – Get Free Report) had its target price boosted by equities researchers at BMO Capital ...

Bank of New York Mellon Corp boosted its holdings in Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Free Report) by 9.7% during the 4th quarter, according to its most recent disclosure with the ...

OSCEOLA COUNTY, Fla. — The Osceola County Sheriff’s Office has arrested 26 suspects in a fentanyl trafficking bust that is ...

Protagonist Therapeutics, Inc.'s VERIFY and ANTHEM-UC studies show breakthroughs in polycythemia vera and ulcerative colitis.

Results from the phase 3 ICONIC-LEAD study presented at this year’s American Academy of Dermatology (AAD) annual meeting ...

The market slump continued yesterday as President Donald Trump's "period of transition" fuels stagflation fears. It led to ...

We recently compiled a list of the 10 Firms Buck Market Bloodbath on Monday. In this article, we are going to take a look at ...

On Monday, Protagonist Therapeutics, Inc. PTGX announced topline results from ANTHEM-UC Phase 2b study of icotrokinra ...

Protagonist Therapeutics shares were up 28% to $49.25 after the company reported positive topline results from a Phase 2b study of icotrokinra, conducted by partner Johnson & Johnson.